Search Results - Amy Harker-Murray
- Showing 1 - 2 results of 2
-
1
-
2
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial by Alain P. Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, Thach-Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. Messino, Dennis F. Moore, Christopher D. Lao, Bryan A. Faller, Rangaswamy Govindarajan, Amy Harker-Murray, Luke Dreisbach, James Moon, Kenneth F. Grossmann, Antoni Ribas
Published 2020Artigo
Search Tools:
Related Subjects
Biology
Cancer
Chemotherapy
Internal medicine
Medicine
Oncology
Randomized controlled trial
Breast cancer
Cancer research
Cell biology
Clinical trial
Dabrafenib
Dosing
Kinase
MAPK/ERK pathway
MEK inhibitor
Melanoma
Metastatic melanoma
Neoadjuvant therapy
Paleontology
Progression-free survival
Randomization
Stage (stratigraphy)
Surgery
Trametinib
Urology
Vemurafenib